GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Invivyd Inc (NAS:IVVD) » Definitions » Other Current Assets

Invivyd (Invivyd) Other Current Assets : $19.51 Mil (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Invivyd Other Current Assets?

Invivyd's other current assets for the quarter that ended in Mar. 2024 was $19.51 Mil.

Invivyd's quarterly other current assets increased from Sep. 2023 ($4.51 Mil) to Dec. 2023 ($23.31 Mil) but then declined from Dec. 2023 ($23.31 Mil) to Mar. 2024 ($19.51Mil).

Invivyd's annual other current assets declined from Dec. 2021 ($25.06 Mil) to Dec. 2022 ($4.55 Mil) increased from Dec. 2022 ($4.55 Mil) to Dec. 2023 ($23.31 Mil).


Invivyd Other Current Assets Historical Data

The historical data trend for Invivyd's Other Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Invivyd Other Current Assets Chart

Invivyd Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Other Current Assets
2.39 25.06 4.55 23.31

Invivyd Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Other Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.66 11.08 4.51 23.31 19.51

Invivyd Other Current Assets Calculation

Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:


Cash
Trade Receivables
Inventory

The assets grouped under other current assets are most commonly:


Prepaid Expenses
Tax Assets
Non-Trade Receivables
Other (too numerous to list)

Some companies can and do choose to report each of these items separately.

Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.

Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.

Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.

Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.

There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.

At most companies, other current assets are a small and unimportant part of the total balance sheet.


Invivyd Other Current Assets Related Terms

Thank you for viewing the detailed overview of Invivyd's Other Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Invivyd (Invivyd) Business Description

Traded in Other Exchanges
N/A
Address
1601 Trapelo Road, Suite 178, Waltham, MA, USA, 02451
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.
Executives
Adimab, Llc 10 percent owner, other: See Remarks 7 LUCENT DRIVE, LEBANON NH 03766
William E. Duke officer: Chief Financial Officer C/O VALERITAS, INC., 750 ROUTE 202 SOUTH, SUITE 600, BRIDGEWATER NJ 08807
Sara Cotter director 1735 MARKET STREET, FLOOR 23, PHILADELPHIA PA 19103
Allen Robert D. Iii officer: Chief Scientific Officer 1601 TRAPELO ROAD, SUITE 178, WALTHAM MA 02451
Stacy Price officer: Chief Tech. and Manuf. Officer 1601 TRAPELO ROAD, SUITE 178, WALTHAM MA 02451
Jeremy Gowler officer: COO & CCO 1601 TRAPELO ROAD, SUITE 178, WALTHAM MA 02451
Rebecca Dabora officer: Chief Tech and Manuf Officer 303 WYMAN STREET, SUITE 300, WALTHAM MA 02451
Peter Schmidt officer: Chief Medical Officer 1601 TRAPELO ROAD, SUITE 178, WALTHAM MA 02451
Jill Andersen officer: Chief Legal Officer, Secretary 303 WYMAN STREET, SUITE 300, WALTHAM MA 02451
Christine Lindenboom director 1601 TRAPELO ROAD, SUITE 178, WALTHAM MA 02451
Frederick W Driscoll officer: Interim CFO
David Hering director, officer: Chief Executive Officer 303 WYMAN STREET, SUITE 300, WALTHAM MA 02451
Marc Elia director, other: See Remarks C/O SQZ BIOTECHNOLOGIES COMPANY, 200 ARSENAL YARDS BOULEVARD, SUITE 210, WATERTOWN MA 02472
M28 Capital Management Lp other: See Remarks 700 CANAL STREET, 2ND FLOOR, STAMFORD CT 06902
Clive Meanwell director, 10 percent owner THE MEDICINES CO, 8 SYLVAN WAY, PARSIPPANY NJ 07054

Invivyd (Invivyd) Headlines

From GuruFocus